» Articles » PMID: 32042347

Towards Extracellular Matrix Normalization for Improved Treatment of Solid Tumors

Overview
Journal Theranostics
Date 2020 Feb 12
PMID 32042347
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

It is currently challenging to eradicate cancer. In the case of solid tumors, the dense and aberrant extracellular matrix (ECM) is a major contributor to the heterogeneous distribution of small molecule drugs and nano-formulations, which makes certain areas of the tumor difficult to treat. As such, much research is devoted to characterizing this matrix and devising strategies to modify its properties as a means to facilitate the improved penetration of drugs and their nano-formulations. This contribution presents the current state of knowledge on the composition of normal ECM and changes to ECM that occur during the pathological progression of cancer. It also includes discussion of strategies designed to modify the composition/properties of the ECM as a means to enhance the penetration and transport of drugs and nano-formulations within solid tumors. Moreover, a discussion of approaches to image the ECM, as well as ways to monitor changes in the ECM as a function of time are presented, as these are important for the implementation of ECM-modifying strategies within therapeutic interventions. Overall, considering the complexity of the ECM, its variability within different tissues, and the multiple pathways by which homeostasis is maintained (both in normal and malignant tissues), the available literature - while promising - suggests that improved monitoring of ECM remodeling is needed to harness the described strategies to their full potential, and match them with an appropriate chemotherapy regimen.

Citing Articles

Emerging Approaches in Glioblastoma Treatment: Modulating the Extracellular Matrix Through Nanotechnology.

Horta M, Soares P, Leite Pereira C, Lima R Pharmaceutics. 2025; 17(2).

PMID: 40006509 PMC: 11859630. DOI: 10.3390/pharmaceutics17020142.


Unlocking Nature's Potential: Ferritin as a Universal Nanocarrier for Amplified Cancer Therapy Testing via 3D Microtissues.

Munir I, Nazir F, Yesiloz G ACS Appl Mater Interfaces. 2024; 16(51):70187-70204.

PMID: 39660468 PMC: 11672483. DOI: 10.1021/acsami.4c12524.


Amelioration of breast cancer therapies through normalization of tumor vessels and microenvironment: paradigm shift to improve drug perfusion and nanocarrier permeation.

Famta P, Shah S, Vambhurkar G, Pandey G, Bagasariya D, Kumar K Drug Deliv Transl Res. 2024; 15(2):389-406.

PMID: 39009931 DOI: 10.1007/s13346-024-01669-9.


Tumor-Agnostic Therapy-The Final Step Forward in the Cure for Human Neoplasms?.

El-Sayed M, Bianco J, Li Y, Fabian Z Cells. 2024; 13(12.

PMID: 38920700 PMC: 11201516. DOI: 10.3390/cells13121071.


Biomaterial-Based Responsive Nanomedicines for Targeting Solid Tumor Microenvironments.

Avgoustakis K, Angelopoulou A Pharmaceutics. 2024; 16(2).

PMID: 38399240 PMC: 10892652. DOI: 10.3390/pharmaceutics16020179.


References
1.
Polydorou C, Mpekris F, Papageorgis P, Voutouri C, Stylianopoulos T . Pirfenidone normalizes the tumor microenvironment to improve chemotherapy. Oncotarget. 2017; 8(15):24506-24517. PMC: 5421866. DOI: 10.18632/oncotarget.15534. View

2.
Mariathasan S, Turley S, Nickles D, Castiglioni A, Yuen K, Wang Y . TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018; 554(7693):544-548. PMC: 6028240. DOI: 10.1038/nature25501. View

3.
Brown E, McKee T, DiTomaso E, Pluen A, Seed B, Boucher Y . Dynamic imaging of collagen and its modulation in tumors in vivo using second-harmonic generation. Nat Med. 2003; 9(6):796-800. DOI: 10.1038/nm879. View

4.
Kudo D, Suto A, Hakamada K . The Development of a Novel Therapeutic Strategy to Target Hyaluronan in the Extracellular Matrix of Pancreatic Ductal Adenocarcinoma. Int J Mol Sci. 2017; 18(3). PMC: 5372616. DOI: 10.3390/ijms18030600. View

5.
Whatcott C, Han H, Posner R, Hostetter G, Von Hoff D . Targeting the tumor microenvironment in cancer: why hyaluronidase deserves a second look. Cancer Discov. 2011; 1(4):291-6. PMC: 3204883. DOI: 10.1158/2159-8290.CD-11-0136. View